Chemotherapy Induced Thrombocytopenia (CIT) refers to a condition of low platelet count caused due to chemotherapy treatment for cancer. Chemotherapy induced thrombocytopenia therapeutics includes various drugs and medications that help manage platelet count and assist in blood clotting during chemotherapy. Some commonly used chemotherapy induced thrombocytopenia therapeutics include thrombopoietin receptor agonists (TPO-RA) such as Eltrombopag and Romiplostim. TPO-RAs help stimulate the production of new platelets in the bone marrow. The growing global cancer prevalence and rising chemotherapy treatment rates are majorly driving the demand for chemotherapy induced thrombocytopenia therapeutics.

The Global Chemotherapy Induced Thrombocytopenia Therapeutics Market is estimated to be valued at US$ 1688.26 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Chemotherapy Induced Thrombocytopenia Therapeutics are Amgen, Inc., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V. Amgen’s Nplate was the first ever FDA approved TPO-RA for chemotherapy induced thrombocytopenia.

The key opportunities in the chemotherapy induced thrombocytopenia therapeutics market include rising healthcare investments in emerging economies of Asia Pacific and Latin America. Additionally, the increasing demand for affordable biosimilar drugs provides opportunities for new market players.

Innovations in biosimilar TPO-RAs are expected to boost the chemotherapy induced thrombocytopenia therapeutics market growth. Some companies are focusing on developing orally bioavailable thrombopoietin receptor agonists to improve patient compliance over injectables.

Market Drivers

Rising global cancer prevalence is a major market driver. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. This will significantly increase the demand for chemotherapy and related therapeutics over the forecast period.

Current Challenges in Chemotherapy Induced Thrombocytopenia Therapeutics Market
Chemotherapy Induced Thrombocytopenia Therapeutics Market has become a major challenge for oncologists as it can potentially lead to chemotherapy dose reductions and delays. The key current challenges in the chemotherapy induced thrombocytopenia therapeutics market include lack of effective drugs, adverse effects associated with existing therapies, and limited understanding of the pathophysiology. Many of the existing drugs have safety issues, drug interactions, and resistance development on long term use. There is an urgent need for new treatment options with improved efficacy and safety profiles to better manage thrombocytopenia in cancer patients undergoing chemotherapy.

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)